Does the media prefer DFTX or PAHC?

In the previous week, Definium Therapeutics and Definium Therapeutics both had 1 articles in the media. Phibro Animal Health's average media sentiment score of 0.50 beat Definium Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MANE or PAHC?

In the previous week, Veradermics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for Phibro Animal Health. Veradermics' average media sentiment score of 0.63 beat Phibro Animal Health's score of 0.50 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PAHC or INDV?

In the previous week, Indivior had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Indivior and 1 mentions for Phibro Animal Health. Indivior's average media sentiment score of 1.26 beat Phibro Animal Health's score of 0.50 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PAHC or RGC?

Phibro Animal Health presently has a consensus price target of $47.67, suggesting a potential upside of 27.45%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, research analysts plainly believe Phibro Animal Health is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, PAHC or RGC?

Phibro Animal Health has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phibro Animal Health $1.52B 1.00 $99.72M $2.44 15.33 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media favor PAHC or RGC?

In the previous week, Regencell Bioscience had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Regencell Bioscience and 1 mentions for Phibro Animal Health. Regencell Bioscience's average media sentiment score of 0.69 beat Phibro Animal Health's score of 0.50 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PAHC or OGN?

In the previous week, Organon & Co. had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.50 beat Organon & Co.'s score of 0.32 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Phibro Animal Health (PAHC) Competitors

$38.30 +0.90 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$38.34 +0.04 (+0.10%)

As of 04:38 PM Eastern

Compare

PAHC vs. DFTX, MANE, INDV, RGC, and OGN

Should you buy Phibro Animal Health stock or one of its competitors? Phibro Animal Health's main competitors and comparable companies include Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), Regencell Bioscience (RGC), and Organon & Co. (OGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phibro Animal Health compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Definium Therapeutics and Definium Therapeutics both had 1 articles in the media. Phibro Animal Health's average media sentiment score of 0.50 beat Definium Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics currently has a consensus price target of $64.88, suggesting a potential upside of 89.80%. Phibro Animal Health has a consensus price target of $47.67, suggesting a potential upside of 27.45%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Definium Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Phibro Animal Health has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.33

Phibro Animal Health has a net margin of 6.57% compared to Definium Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Phibro Animal Health	6.57%	37.86%	9.18%

Definium Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 48.5% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Phibro Animal Health beats Definium Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Phibro Animal Health compare to Veradermics?

Veradermics (NYSE:MANE) and Phibro Animal Health (NASDAQ:PAHC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Phibro Animal Health has a net margin of 6.57% compared to Veradermics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Phibro Animal Health	6.57%	37.86%	9.18%

99.3% of Phibro Animal Health shares are held by institutional investors. 48.5% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Veradermics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for Phibro Animal Health. Veradermics' average media sentiment score of 0.63 beat Phibro Animal Health's score of 0.50 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 20.81%. Phibro Animal Health has a consensus target price of $47.67, suggesting a potential upside of 27.45%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Phibro Animal Health has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.33

Summary

Phibro Animal Health beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 48.5% of Phibro Animal Health shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Phibro Animal Health presently has a consensus target price of $47.67, suggesting a potential upside of 27.45%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 27.41%. Given Phibro Animal Health's higher probable upside, research analysts plainly believe Phibro Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Indivior had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Indivior and 1 mentions for Phibro Animal Health. Indivior's average media sentiment score of 1.26 beat Phibro Animal Health's score of 0.50 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Indivior has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Indivior has a net margin of 26.65% compared to Phibro Animal Health's net margin of 6.57%. Phibro Animal Health's return on equity of 37.86% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Indivior	26.65%	-283.11%	36.85%

Indivior has lower revenue, but higher earnings than Phibro Animal Health. Indivior is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.33
Indivior	$1.24B	3.38	$210M	$2.79	12.71

Summary

Indivior beats Phibro Animal Health on 10 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Regencell Bioscience?

Phibro Animal Health (NASDAQ:PAHC) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Phibro Animal Health has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.33
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Regencell Bioscience had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Regencell Bioscience and 1 mentions for Phibro Animal Health. Regencell Bioscience's average media sentiment score of 0.69 beat Phibro Animal Health's score of 0.50 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 48.5% of Phibro Animal Health shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.57% compared to Regencell Bioscience's net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Regencell Bioscience	N/A	N/A	N/A

Phibro Animal Health presently has a consensus price target of $47.67, suggesting a potential upside of 27.45%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, research analysts plainly believe Phibro Animal Health is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Phibro Animal Health has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

Phibro Animal Health beats Regencell Bioscience on 11 of the 14 factors compared between the two stocks.

How does Phibro Animal Health compare to Organon & Co.?

Phibro Animal Health (NASDAQ:PAHC) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Phibro Animal Health has a net margin of 6.57% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Phibro Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Organon & Co.	3.41%	88.97%	6.03%

Phibro Animal Health pays an annual dividend of $0.48 per share and has a dividend yield of 1.3%. Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Phibro Animal Health pays out 19.7% of its earnings in the form of a dividend. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 48.5% of Phibro Animal Health shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Phibro Animal Health has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.33
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.89

In the previous week, Organon & Co. had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.50 beat Organon & Co.'s score of 0.32 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phibro Animal Health presently has a consensus target price of $47.67, suggesting a potential upside of 27.45%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.25%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, research analysts clearly believe Phibro Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Phibro Animal Health beats Organon & Co. on 12 of the 19 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.55B	$12.35B	$7.19B	$13.28B
Dividend Yield	1.27%	2.65%	2.53%	16.36%
P/E Ratio	15.70	795.15	274.47	26.16
Price / Sales	1.02	835.72	585.00	81.25
Price / Cash	8.25	86.17	76.82	53.72
Price / Book	4.03	10.71	11.21	6.34
Net Income	$99.72M	$2.84B	$3.50B	$381.90M
7 Day Performance	2.85%	-0.96%	-0.83%	-1.36%
1 Month Performance	4.08%	-5.81%	-5.42%	-4.29%
1 Year Performance	3.04%	-5.29%	4.36%	-0.33%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.4644 of 5 stars	$38.30 +2.4%	$47.67 +24.5%	+0.8%	$1.55B	$1.52B	15.70	2,605
DFTX Definium Therapeutics	2.8656 of 5 stars	$35.62 -1.7%	$64.88 +82.1%	+166.8%	$4.79B	N/A	N/A	40	Analyst Forecast
MANE Veradermics	1.7513 of 5 stars	$109.43 -7.9%	$153.00 +39.8%	N/A	$4.57B	N/A	N/A	21	News Coverage
INDV Indivior	4.3731 of 5 stars	$35.90 -0.3%	$45.17 +25.8%	+47.3%	$4.24B	$1.24B	12.87	838	Positive News
RGC Regencell Bioscience	0.5394 of 5 stars	$7.35 +1.5%	N/A	-60.7%	$3.63B	N/A	N/A	10	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. DFTX, MANE, INDV, RGC, and OGN

How does Phibro Animal Health compare to Definium Therapeutics?

Summary

How does Phibro Animal Health compare to Veradermics?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to Regencell Bioscience?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. DFTX, MANE, INDV, RGC, and OGN

How does Phibro Animal Health compare to Definium Therapeutics?

Does the media prefer DFTX or PAHC?

Do analysts rate DFTX or PAHC?

Which has stronger valuation and earnings, DFTX or PAHC?

Is DFTX or PAHC more profitable?

Which has more risk & volatility, DFTX or PAHC?

Do insiders and institutionals have more ownership in DFTX or PAHC?

Summary

How does Phibro Animal Health compare to Veradermics?

Is MANE or PAHC more profitable?

Do institutionals & insiders have more ownership in MANE or PAHC?

Does the media prefer MANE or PAHC?

Do analysts rate MANE or PAHC?

Which has higher valuation & earnings, MANE or PAHC?

Summary

How does Phibro Animal Health compare to Indivior?

Do insiders and institutionals hold more shares of PAHC or INDV?

Do analysts rate PAHC or INDV?

Does the media refer more to PAHC or INDV?

Which has more risk & volatility, PAHC or INDV?

Is PAHC or INDV more profitable?

Which has better earnings & valuation, PAHC or INDV?

Summary

How does Phibro Animal Health compare to Regencell Bioscience?

Which has higher earnings and valuation, PAHC or RGC?

Does the media favor PAHC or RGC?

Do insiders & institutionals have more ownership in PAHC or RGC?

Is PAHC or RGC more profitable?

Do analysts prefer PAHC or RGC?

Which has more volatility and risk, PAHC or RGC?

Summary

How does Phibro Animal Health compare to Organon & Co.?

Is PAHC or OGN more profitable?

Is PAHC or OGN a better dividend stock?

Do institutionals and insiders hold more shares of PAHC or OGN?

Which has more risk and volatility, PAHC or OGN?

Which has higher earnings and valuation, PAHC or OGN?

Does the media refer more to PAHC or OGN?

Do analysts recommend PAHC or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools